Rising Global Cancer Incidence Fuels Growth In The Desmoid Tumor Market: The Driving Engine Behind Desmoid Tumors Market Evolution in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Desmoid Tumors Market Size Growth Forecast: What to Expect by 2025?
The valuation of the desmoid tumors market has experienced significant expansion recently, projected to increase from $2.97 billion in the year 2024 to reach $3.15 billion by 2025, reflecting a compound annual growth rate of 6.3%; this upward trajectory during the historical span is largely explainable by progress in diagnostic imaging techniques, deeper insights gained from genetic studies, novel surgical procedures, heightened public and professional awareness alongside educational initiatives, and the dedicated efforts of patient support groups.

How Will the Desmoid Tumors Market Size Evolve and Grow by 2029?
Anticipation surrounds the desmoid tumors market, projecting robust expansion through the coming years, aiming for a valuation of $4.08 billion by 2029, propelled by a compound annual growth rate (CAGR) of 6.7%; this upward trajectory is fundamentally driven by developments in targeted therapeutics, the integration of personalized medical strategies, broadening global partnerships, the validation of new treatments by regulatory bodies, and a shifting focus towards patient-centered care models, all while the market landscape is being shaped by significant movements such as breakthroughs in therapeutic methodologies, the emergence of precision medicine alongside biomarker identification, heightened activity in clinical investigation and research endeavors, reliance on integrated, multidisciplinary care units, and amplified patient advocacy and support efforts.

View the full report here:
https://www.thebusinessresearchcompany.com/report/desmoid-tumors-global-market-report

What Drivers Are Propelling the Growth of Desmoid Tumors Market Forward?
The escalating incidence of cancer is anticipated to be a key factor stimulating the expansion of the desmoid tumor market in the near future. Cancer itself is characterized as a group of conditions involving the body's abnormal cells multiplying and disseminating unchecked, capabilities which allow these rogue cells to invade adjacent organs and tissues, thereby causing damage. This global upswing in cancer diagnoses has consequently boosted the need for sophisticated and potent chemotherapeutic treatments, which exerts a favorable effect on the desmoid tumor market trajectory. Demonstrating this trend, data released by the National Cancer Institute, a U.S. federal entity, indicated that projections for 2024 suggest approximately 2,001,140 new cancer diagnoses across the United States, with an anticipated 611,720 fatalities attributed to the illness. Globally, the year 2022 saw nearly 20 million new cases and about 9.7 million deaths linked to cancer; furthermore, forecasts project that by 2040, the annual figure for new cancer cases will climb to 29.9 million, while cancer-related deaths could reach 15.3 million. Consequently, the continually increasing prevalence of cancer serves as a primary catalyst for the growth observed in the desmoid tumor market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13228&type=smp

Which Emerging Trends Are Transforming the Desmoid Tumors Market in 2025?
Key industry players within the desmoid tumors sector are focusing on creating cutting-edge pharmaceuticals, exemplified by nirogacestat, aimed at providing enhanced therapeutic solutions for their established patient bases. This promising agent, nirogacestat, functions as an orally administered, low-molecular-weight compound that inhibits gamma-secretase activity. To illustrate this progress, February 2023 saw SpringWorks Therapeutics Inc., a biopharmaceutical firm situated in the US and currently in the clinical development stage, receive confirmation from the U.S. Food and Drug Administration (FDA) regarding their new drug application (NDA) for nirogacestat, designated for adult sufferers of desmoid tumors, even gaining priority review status. The mechanism of action for nirogacestat is hypothesized to involve the suppression of notch protein synthesis, a pathway believed to induce the demise of malignant cells, given that desmoid tumors frequently exhibit elevated concentrations of this growth-promoting notch protein. Consequently, nirogacestat represents a novel therapeutic avenue for patients, potentially leading to more favorable clinical results.

What Are the Key Segments in the Desmoid Tumors Market?
The desmoid tumorsmarket covered in this report is segmented -

1) By Treatment: Surgery; Radiation Therapy; Anti-Inflammatory Medication; Hormone Therapy; Chemotherapy; Novel Molecular-Targeted Therapy; Other Treatments
2) By Diagnosis: Biopsy; Electron Microscopic Examination; Immunohistochemical Analysis; Other Diagnosis
3) By End-User: Hospitals And Clinics; Specialty Centers; Other End-Users

Subsegments:
1) By Surgery: Wide Excision; Minimally Invasive Surgery
2) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy
3) By Anti-Inflammatory Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Corticosteroids
4) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors
5) By Chemotherapy: Traditional Chemotherapy Agents; Combination Chemotherapy
6) By Novel Molecular-Targeted Therapy: Tyrosine Kinase Inhibitors; Other Targeted Therapies
7) By Other Treatments: Watchful Waiting; Physical Therapy; Pain Management Strategies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13228&type=smp

Who Are the Key Players Shaping the Desmoid Tumors Market's Competitive Landscape?
Major companies operating in the desmoid tumors market report are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Abbott Laboratories, Amgen Inc., Stryker Corporation, Genome And Company, Vertex Pharmaceuticals Incorporated, Eisai Limited, Beckman Coulter Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Ionis Pharmaceuticals Inc., Ayala Pharmaceuticals Inc., Blueprint Medicines Corporation, Xencor Inc., MacroGenics Inc., Debiopharm Group, Clovis Oncology Inc., Juno Therapeutics Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG

What Geographic Markets Are Powering Growth in the Desmoid Tumors Market?
North America was the largest region in the desmoid tumors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the desmoid tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13228

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.